TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI

NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab to accelerate drug discovery and pharmaceutical manufacturing. The companies will invest up to $1 billion over five years in the San Francisco Bay Area facility, combining Lilly's pharmaceutical expertise with NVIDIA's AI and computing capabilities. The lab will focus on creating continuous learning systems connecting wet labs with computational resources, using NVIDIA's BioNeMo platform and Vera Rubin architecture to build advanced AI models for drug development.

Insights
NVDA   positive

NVIDIA is positioned as a key technology partner providing critical AI infrastructure, computing platforms (BioNeMo, Vera Rubin), and expertise. The partnership validates NVIDIA's AI leadership in life sciences and expands its addressable market in pharmaceutical R&D, representing significant business opportunity and strategic positioning.